Bausch Health (BHC) Q2 2026 Earnings Call Transcript

Bausch Health (ex Bausch + Lomb) delivered another 13th consecutive quarter of growth, reporting Q2 revenue of $1.458B (+16% YoY) and adjusted EBITDA of $865M (+28% YoY), with adjusted EBITDA margin expanding 530 bps to 59.3%. Management raised full-year 2026 guidance: revenue to $5.35B–$5.50B (+$100M at midpoint), adjusted EBITDA to $3.025B–$3.100B (+$150M), and adjusted cash flow from ops to $1.4B–$1.475B (+$200M). Offsetting headwinds include an anticipated $150M channel inventory impact in 2H26 plus $50M from Aplenzin loss of exclusivity and $75M from Medicaid/340B erosion, though 2027 adjusted EBITDA guidance of $2.7B was maintained.

Analysis

The equity story is still a leverage-and-deleveraging trade, not a clean fundamentals rerate. The incremental value is coming from one operating lever that can scale quickly, but the market will discount it until management shows that the margin expansion is reproducible without temporary channel mix benefits or one-off working-capital help. That means the stock can work over weeks, but the higher-quality catalyst path is 1-3 months: confirm Q3/Q4 run-rate and any concrete Bausch + Lomb monetization step.

The bigger second-order effect is competitive: the company’s tighter commercial execution in GI and aesthetics should pressure smaller private-label and regional rivals that rely on weaker distribution, while the China distributor integration raises the bar for peers trying to profitably scale medical aesthetics in APAC. However, the same operating model also creates a sharper cliff if reimbursement or exclusivity assumptions break, because a meaningful part of the implied 2027 bridge still depends on preserved pricing power rather than durable unit growth.

Consensus looks too focused on the beat and not enough on the fact that the medium-term guide is intentionally conservative because management sees visible headwinds ahead. That makes the near-term sentiment constructive but fragile: if the market believes the Q4 gross-to-net accrual or 2027 rebate drag is larger than expected, the multiple can compress quickly despite raised 2026 guidance. The contrarian read is that the balance sheet is improving, but the stock may still be under-earning its valuation until there is proof that the asset mix can generate equity value even after the transitory tailwinds fade.

Key Decisions for Investors

• Long BHC common on a 4-8 week horizon into any post-earnings digestion, with a stop if the stock fails to hold the pre-print breakout level after management commentary on Q4 accruals; risk/reward is attractive only if the market keeps discounting the 2026 run-rate rather than the 2027 reset.
• Prefer BHC Jan-2027/Jan-2028 call spreads over outright stock for upside to a Bausch + Lomb monetization catalyst; this caps theta while preserving exposure to a structural rerating if management announces a credible capital event within 1-3 months.
• Pair trade: long BHC / short a reimbursement-sensitive specialty pharma basket over the next quarter to isolate company-specific margin execution versus CMS-related pressure; thesis breaks if Xifaxan litigation or rebate leakage proves worse than implied.
• Set an alert on any update to the Xifaxan exclusivity timeline; if the market starts pricing a faster erosion path, the 2027 EBITDA anchor should be treated as too high and the long should be reduced immediately.
• If the stock rallies sharply into the print, take profits rather than chase: this is a better buy-on-dips name than a momentum long because the next visible catalyst is binary and the downside is driven by guidance normalization, not by a collapsing business.